Alembic Pharmaceuticals Limited — Important, 03-02-2025: Financial Result Updates

Consolidated revenues for the quarter ended December 31, 2024, stood at ₹1,702.25 crore, reflecting a growth of 2.8% year-over-year compared to ₹1,633.46 crore in the same quarter last year. This growth can be attributed to increased demand in domestic markets and improved operational efficiency despite previous disruptions from natural calamities.

Net profit for the quarter was ₹177.78 crore, a significant recovery from a net profit of ₹166.00 crore a year ago. The basic and diluted EPS for this period came in at ₹0.87. The profitability increase is primarily due to effective cost management and recovering sales post-operations resumption.

Total expenses for the quarter grew by 4.6% year-over-year, driven by higher material costs and a rise in employee benefits expense, contributing to operational cost pressures. The overall operational costs reflect the company’s efforts to maintain efficiency amidst recovery phases.

On the balance sheet, total net worth is approximately ₹5,041.04 crore, indicating a solid equity position as the debt-equity ratio remains stable at 0.20. The current ratio is also healthy at 1.71, suggesting sufficient liquidity.

Looking ahead, Alembic Pharmaceuticals appears focused on sustaining growth through market expansion and enhancing production capabilities. Given the solid financial results and strategic outlook, investors might consider this a 'buy' opportunity, based on the potential for continued operational recovery and market growth prospects.